Orchid Pharma Ltd (ORCHPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Orchid Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Announcement under regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A.
Press Release · 24 Oct 2026, 10:33 pm
Orchid Pharma Signs $80M Latin America Licensing Deal for Exblifep Orchid Pharma Ltd. entered a licensing and supply agreement on 24th Oct'26 with Laboratorio Libra S.A. to expand its novel antibiotic Exblifep across nine Latin American markets, including Chile, Costa Rica, Ecuador, and Uruguay. Orchid will manufacture and supply finished dosage forms, while Libra holds exclusive registration, import, and marketing rights. The 10-year partnership presents an estimated $80 million commercial opportunity based on projected regional demand. Commercial rollouts remain subject to local regulatory approvals.
Outcome of Board Meeting for Raising Funds ("Enabling Resolution")
Others (Uncategorized) · 20 Oct 2026, 5:52 pm
Orchid Pharma Approves Enabling Resolution to Raise up to Rs. 600 Crore The Board of Directors of Orchid Pharma Limited, at its meeting held on 20th Oct'26, approved an enabling resolution to explore fundraising of up to Rs. 600 crore. The capital may be raised through equity shares, convertible debentures, or other eligible securities via Qualified Institutions Placement (QIP), preferential issue, private placement, public issue, or other permissible modes, subject to requisite shareholder and regulatory approvals. Specific issuance structures and terms remain to be finalized.
Outcome of Board Meeting
Outcome · 20 Oct 2026, 5:43 pm
Orchid Pharma Board Approves Enabling Resolution to Raise up to Rs 600 Crore The Board of Directors of Orchid Pharma Limited, at its meeting on 20th Oct'26, approved an enabling resolution to explore raising funds for an indicative amount of up to Rs 600 crore. The capital may be raised via equity shares, convertible debentures, or other eligible securities through modes including Qualified Institutions Placement (QIP), private placement, preferential issue, or public issue. The fundraise remains subject to necessary shareholder, statutory, and regulatory approvals.
ORCHID PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 20-Oct-2026 to consider Fund raising.
Intimation · 16 Oct 2026, 1:47 am
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting ....
Intimation · 16 Oct 2026, 1:43 am
Orchid Pharma Board to Consider Fund Raising Options on 20th Oct'26 Orchid Pharma Limited has scheduled a Board of Directors meeting on 20th Oct'26 to evaluate multiple fund-raising avenues. Proposed structures include issuing equity shares, fully or partly convertible debentures, composite non-convertible debentures with warrants, or other eligible securities. The capital raise may occur via qualified institutional placement (QIP), preferential allotment, private placement, public issues, or alternative permissible modes, subject to requisite regulatory and shareholder approvals.
Scrutinizer''s Report and Voting Result-33rd Annual General Meeting of Orchid Pharma Limited
Annual General Meeting · 03 Oct 2026, 6:16 pm
Proceedings of 33rd Annual General Meeting of Orchid Pharma Limited Held on 29th September 2026
Annual General Meeting · 30 Sept 2026, 12:12 am
Intimation under regulation 30- Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation
Others (Uncategorized) · 24 Sept 2026, 1:30 am
Orchid Pharma Obtains Trading Approval for 4.46 Crore Amalgamation Shares Orchid Pharma Limited received trading approval from the NSE and BSE for 4,45,86,052 equity shares, effective 23rd Sep'26. These shares were previously allotted on 1st Aug'26 pursuant to an NCLT Chennai-approved Scheme of Amalgamation. With listing and trading formalities completed across both exchanges, the newly allotted shares are now fully admitted to dealings, expanding the company's freely tradable equity base.
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
Others (Uncategorized) · 23 Sept 2026, 2:52 am
Orchid Pharma Acquires Kancheepuram Land, Resolving Dispute With DBS Bank Orchid Pharma has purchased land situated at Patibulum Village, Kancheepuram District, Tamil Nadu, following its earlier disclosure on 6th Jun'25 regarding a lease rental dispute. The acquisition concludes the previous lease arrangement and fully terminates DBS Bank India Limited's rights and interests in the property. This transaction marks the permanent closure of the company's arrangement with DBS Bank India, establishing absolute clarity and certainty regarding Orchid Pharma's complete ownership of the asset.
Investor roadshow scheduled to be held in Mumbai
Others (Uncategorized) · 21 Sept 2026, 11:40 pm
Orchid Pharma Schedules Three-Day Physical Investor Roadshow in Mumbai Orchid Pharma announced that Whole Time Director Mridul Dhanuka will participate in a physical Investor Roadshow in Mumbai from 28th Sep'26 to 30th Sep'26. The group meetings are subject to change based on unforeseen exigencies, and the company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the interactions.
Annual Report of the Company for FY 2025-26.
Others (Uncategorized) · 09 Sept 2026, 2:05 am
Business Responsibility and Sustainability Report for FY 2025-26
Others (Uncategorized) · 08 Sept 2026, 9:32 pm
Orchid Pharma Releases FY25-26 BRSR Highlighting Operational and Sustainability Metrics Orchid Pharma reported FY25-26 standalone turnover of ₹1,23,277.84 lakh and net worth of ₹1,64,667.59 lakh, with Active Pharmaceutical Ingredients (APIs), primarily Cephalosporin, generating 97% of total revenue. Exports contributed 64.55% across 52 countries. Total energy consumption stood at 1,498.12 Joules, with renewable sources comprising 68% of electricity and wind/solar usage. Total Scope 1 and Scope 2 GHG emissions declined to 54,412.00 metric tonnes and 12,806.00 metric tonnes of CO2 equivalent, respectively. The company maintains a 100% Zero Liquid Discharge system across its operations.
Notice of 33rd Annual General Meeting of the Company
Annual General Meeting · 08 Sept 2026, 5:27 am
Appointment of cost auditor for FY 2026-27 and change in designation of director.
Change in Management · 04 Sept 2026, 1:59 am
Orchid Pharma Elevates Arjun Dhanuka to Whole-Time Director and Appoints Cost Auditor On 3rd Sep'26, Orchid Pharma's board approved elevating Mr. Arjun Dhanuka from Non-Executive to Whole-Time Director for a five-year term ending 2nd Sep'31. The board also appointed M/s. J Karthikeyan & Associates as Cost Auditors for FY 2026-27. Furthermore, the company scheduled its 33rd AGM for 29th Sep'26, establishing 22nd Sep'26 as the cut-off date for e-voting eligibility. The remote e-voting window will operate from 26th Sep'26 to 28th Sep'26.
Outcome of Board meeting.
Others (Uncategorized) · 04 Sept 2026, 1:46 am
Orchid Pharma Appoints Whole-Time Director and Schedules FY27 AGM On 3rd Sep'26, Orchid Pharma's board appointed Mr. Arjun Dhanuka as Whole-Time Director for a five-year term ending 2nd Sep'31, transitioning him from his previous Non-Executive role. The board also approved M/s. J Karthikeyan & Associates as Cost Auditors for FY27. Furthermore, the company scheduled its 33rd AGM for 29th Sep'26, establishing 4th Sep'26 as the cut-off date for shareholder notice eligibility. Remote e-voting for the upcoming AGM resolutions will be conducted from 26th Sep'26 to 28th Sep'26.
Orchid Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
Outcome · 04 Sept 2026, 1:41 am
Orchid Pharma Appoints New Whole-Time Director and Sets 33rd AGM Date Orchid Pharma's board approved Mr. Arjun Dhanuka's elevation to Whole-Time Director for a five-year term effective 3rd Sep'26, transitioning him from a non-executive role. The board also appointed M/s. J Karthikeyan & Associates as Cost Auditor for FY27, pending shareholder ratification. Furthermore, the company scheduled its 33rd Annual General Meeting for 29th Sep'26. The cut-off date for AGM notice eligibility is set for 4th Sep'26, with the e-voting eligibility cut-off on 22nd Sep'26.
Transcript of Analysts/Investors earning call held with public at large on August 21, 2026.
Transcript · 24 Aug 2026, 11:49 pm
Audio Recording of the Analyst/Investor Earning Call for Q-1 ended on June 30, 2026
Audio / Video · 22 Aug 2026, 1:48 am
Orchid Pharma: Q1 FY27 Earnings Call Audio Recording Available Orchid Pharma has uploaded the audio recording of its analyst and investor earnings call held on 21 Aug'26. The call discussed the unaudited standalone and consolidated financial results for Q1 FY27, the quarter ended 30 Jun'26. The company confirmed the event was an audio-only conference call, and the recording is now available on its website.
Investors Presentation-Quarter 1 of F.Y.2026-27, ended on June 30, 2026.
Investor Presentation · 20 Aug 2026, 11:39 pm
Orchid Pharma: Q1FY27 EBITDA Jumps 178% YoY on Strong Revenue Growth Orchid Pharma reported strong Q1 FY27 standalone results, with Revenue from Operations growing 16% YoY to ₹304 Cr. EBITDA surged 178% YoY to ₹25 Cr from ₹9 Cr, with the EBITDA margin expanding to 8% from 3% in Q1 FY26. The company reversed a prior-year loss, posting a Profit After Tax (PAT) of ₹12 Cr compared to a loss of ₹3 Cr. This performance reflects post-amalgamation strength following the integration of Dhanuka Laboratories Ltd., effective from 10 Jul'26.
Intimation of schedule of Analysts/Investors Earning call for the Quarter-1 ended on June 30, 2026.
Intimation · 21 Aug 2026, 3:00 pm
Orchid Pharma Schedules Q1FY27 Investor Call for August 21 Orchid Pharma has scheduled an analyst and investor earnings call for its Q1FY27 results on Fri, Aug 21, '26, at 3:00 PM IST. The call, hosted by Systematix Institutional Equities, will discuss the company's financial performance for the quarter ended Jun 30, '26. Management representation will include the Managing Director, Whole Time Director, and Chief Financial Officer.
Statement of Deviation or variation for the quarter ended June 30, 2026 on the use of proceeds of Funds raised through Qualified Institutional Placement.
Others (Uncategorized) · 15 Aug 2026, 1:41 am
Orchid Pharma Varies QIP Fund Use; Jammu Facility Delayed Orchid Pharma has reported a variation in the use of its Rs 400 crore QIP proceeds from Jun '23. Following shareholder approval on Sep 20, '25, the company has reallocated funds due to changing business needs. The project to set up a new API block in Alathur has been postponed. Consequently, allocations for the Jammu manufacturing facility and debt repayment have been increased. However, the Jammu facility is facing significant delays, with commercial operations now expected by Feb '27 instead of the original timeline.
Monitoring Agency Report for Quarter-1 of F.Y. 2026-27 ended June 30, 2026.
Others (Uncategorized) · 15 Aug 2026, 12:33 am
Orchid Pharma Q1 FY27 QIP Utilization: Project Delays and Fund Reallocation Orchid Pharma has revised the allocation of its Rs. 400 crore QIP proceeds following shareholder approval on 20 Sep'25. The budget for the Jammu manufacturing facility was increased from Rs. 90 crore to Rs. 135 crore, and debt repayment allocation rose from Rs. 141 crore to Rs. 195.46 crore. Conversely, the Alathur API facility budget was cut from Rs. 99.82 crore to just Rs. 0.36 crore. Significant delays have pushed the Jammu plant's expected commercial launch to Feb'27. As of 30 Jun'26, Rs. 357.16 crore has been utilized, leaving Rs. 37.38 crore unspent.
Revised Audited financial results for the Financial year ended March 31, 2026 pursuant to Scheme of Merger
Outcome · 15 Aug 2026, 12:23 am
Orchid Pharma Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 36,833 (+3.1% YoY | +21.6% QoQ) ■ EBITDA: 3,016 (-0.9% YoY | +405.0% QoQ) ■ EBITDA Margin (%): 8.2 (-33 bps YoY | +622 bps QoQ) ■ PAT: 2,584 (-24.1% YoY | Loss to Profit QoQ) ■ EPS (INR): 4.31 (-24.1% YoY | Loss to Profit QoQ)
Financial Results for Quarter-1 of F.Y. 2026-27 ended on June 30, 2026.
Financial Result · 15 Aug 2026, 12:11 am
Outcome of Board meeting inter alia for considering and approving Unaudited Financial Results for Quarter-1 of F.Y. 2026-27, ended on June 30, 2026.
Outcome · 15 Aug 2026, 12:03 am